Suven announces merger of Cohance Lifesciences
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Varenicline is indicated for smoking cessation in adults
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
Subscribe To Our Newsletter & Stay Updated